Darifenacin Tablet, Extended Release
Product Images NDC 62332-224

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 62332-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Darifenacin 15 mg

This is a description of a medicine tablet. The tablet contains 17858 mg of arfbnecn-NG 62332-224-30 ctomide loprole 13 dfenacn B&o. The usual dosage is one tablet per day. The tablet has to be stored at 25°C (77°F) and excursions are permitted. The tablet is an extended-release type and measures 28x30mm. It is not to be taken by people who are not prescribed by the doctor as it is a prescription medicine. The manufacturer is Alembic Pharmaceuticals Limited. The address of the manufacturer is given below.*

FDA Label Image

Darifenacin 2a

FDA Label Image

Darifenacin 2b

FDA Label Image

Darifenacin 2c

FDA Label Image

Darifenacin 7 5 mg

Each tablet contains 8929 mg of Darifenacin and provides 75 mg of Darifenacin. The recommended dosage is one tablet daily. Darifenacin is an extended-release medication. Not available.*

FDA Label Image

Figure 1 (Darifenacin Figure1)

This text is a table showing the mean plasma concentration of Darifenacin in ng/mL over a 24-hour period at different time points post-dose. The concentrations were measured in a group of individuals, including 95 EMs and 6 PMs for a 7.5mg dose and 104 EMs and 10 PMs for a 15mg dose.*

FDA Label Image

Darifenacin Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.